'In Vitro Diagnostic Market Revenues Will Reach $81bn in 2017' Shows New Visiongain Report

LONDON, March 20, 2013 /PRNewswire/ --

A new report by visiongain predicts that world in vitro diagnostic market revenues overall will reach $81.0bn in 2017. That market generated $51.6bn in 2012, according to Medical Device Leader Series: Top In Vitro Diagnostics Companies 2013-2023, published in March 2013. That study analyses the leading companies shaping that market from 2013 onwards, showing their activities, technologies and potential revenues. Visiongain is a business information provider based in London, UK.

The world market for in vitro diagnostic (IVD) products is a large and profitable segment of the healthcare industry. The IVD market is dominated by leading pharma companies, with Roche, Abbott and J&J occupying three of the top 10 IVD market positions. The competitors are a diverse group including large conglomerates Siemens and Danaher, as well as smaller specialist companies (bioMérieux, Bio-Rad and Sysmex) focused entirely on diagnostic products. In 2011, the top 10 in vitro diagnostics manufacturers accounted for 71.3% of global revenues for that overall industry. US-based manufacturers led the worldwide in vitro diagnostics market, with six companies in the top 10 list.

Visiongain forecasts that the overall market for in vitro diagnostic products will grow steadily to 2023. From 2013, revenue growth in that market will be stimulated by technological advances. These will provide improved diagnostic tools offering better treatment monitoring and faster response times. The future will also bring increased availability of over-the-counter (OTC) tests, which patients can perform in the comfort and convenience of their homes.

Dr Syed Ahmed, a senior healthcare industry analyst in visiongain, said: "The in vitro diagnostics market is driven by an increasing prevalence of age-related disorders such as cardiovascular diseases, diabetes, cancer and infectious diseases. A key market driver promoting growth in the IVD sector is the regular requirement for diagnostic testing of infections such as MRSA in hospital settings. Also, with new pathogens such as seasonal influenza strains developing each year, the demand for diagnostic testing is on the rise. It is estimated that diagnostic tests provide over 60% of information held in patient accounts. The rising awareness in the public and the growing pressures on healthcare providers for improved diagnostic products and technologies that can provide early and correct clinical diagnosis for management of disease is delivering sustained growth in the IVD sector.

"The demand for IVD products will continue to grow in the coming decade. The market is highly competitive with several hundred players competing for market share. Roche continues to dominate the industry via its wide product portfolio. IVD manufacturers are striving to develop novel, accurate, easy-to-use, safe and convenient products that can provide patients with diagnostic testing options."

That new study analyses 18 prominent IVD developers and manufacturers, with separate chapters on leading US, European and Japanese companies, and emerging firms. That work also explores associated organisations. It analyses how sales of IVD tests can increase and producers' revenues grow. That investigation shows IVD revenue forecasts to 2023 for 11 companies, and the overall industry, with historical data, growth rates and market shares. Also, it assesses business outlooks and research and development (R&D).

Medical Device Leader Series: Top In Vitro Diagnostics Companies 2013-2023 adds to visiongain's range of analytical reports on industries and markets for healthcare technologies.

For sample pages and further information concerning the visiongain report the Device Leader Series: Top In Vitro Diagnostics Companies 2013-2023, please visit: http://www.visiongain.com/Report/998/Medical-Device-Leader-Series-Top-In-Vitro-Diagnostics-Companies-2013-2023

For an executive summary please contact Sara Peerun sara.peerun@visiongainglobal.com; Tel: +44-(0)20-7336-6100

Companies Listed

3M
AB Sciex
Abbott Laboratories
Abvee
Accuri Cytometers
Agendia
Agilent Technologies
Alacris Theranostics GmbH
Alere
Amgen
Analytical Technologies division of
Arca biopharma
ARGENE
Arkray
AstraZeneca
Banner Alzheimer's Institute
Bayer
Bayer Diagnostics
BD Pharmaceutical Systems
BD Technologies
Beckman Coulter
Becton, Dickinson and Company (BD)
Biocartis
BioMarin Pharmaceutical
bioMérieux
Bio-Rad
Boehringer Ingelheim
Bristol-Myers Squibb
Cancer Research Technology
Cardiogenics
Carmel Pharma AB
Celldex Therapeutics
Cellestis
Cellomics
Centre for Devices and Radiological Health (CDRH)
Cephalon
Chugai Pharmaceuticals
Claros Diagnostics
Clearstone Central Laboratories
CLIA laboratory
Clovis
Cole-Parmer
Compendia Bioscience
Crescendo Bioscience
Dako (Agilent Technologies)
Danaher
DePuy
Dionex
DxS (Now QIAGEN Manchester)
Eli Lilly
Epitomics
ESE GmbH
EskoArtwork
Euronext Amsterdam
Euronext Brussels
Euronext Paris Market
European Commission
European Diagnostic Manufacturers Association (EDMA)
European Union (EU)
Explera s.r.l
Expression Diagnostics
Fermentas
Fisher Scientific
Food and Drug Administration (US FDA)
Fujirebio
Furuno Electric Co.
Genentech
Genomic Health
GenProbe
Genzyme Genetics
GlaxoSmithKline (GSK)
Hoffman La Roche
Hologic
Ibis Biosciences
IDEXX Laboratories
IGEN International
Illumina
Institut Pasteur
Institute Merieux
Instrumentation Labs
Ipsen
Ipsogen
Janssen Diagnostics
Janssen Pharmaceutica
JEOL Ltd.
John Hopkins University
Johnson & Johnson (J&J)
Katakura Industries
KIESTRA Lab Automation
Knome
LabCorp
LabIndia
Laboratory Corporation of America (LabCorp)
Leica Biosystems,
Leica Microsystems
Life Technologies
Luminex
Lyon Civil Hospitals
Massachusetts General Hospital
MDS
MDxHealth
Medco Health Sciences
Merck & Co.
Mindray
Miraca Life Sciences
Monogram Biosciences
Myriad Genetics
Myriad RBM
Nalgene
National Cancer Institute (NCI, US)
National Institutes of Health (NIH, US)
Navigenics
New York Stock Exchange (NYSE)
Newcastle University
Novartis
Oncomed
OncoMethylome
Ortho Biotech Oncology Research & Development (ORD)
Ortho-Clinical Diagnostics
PathWorks Diagnostics
Pfizer
Phadia
Pharma Mar
Pierce Protein Research
Polymedco Inc.
QIAGEN
QuantaLife
Quest Diagnostics
Radiometer
Response Biomedical Corporation
Roche
Roche Applied Science
Rules-Based Medicine
SABiosciences Corporation
Saladax
Schering Plough
SDIX
Siemens Healthcare
Sirigen Group Limited
STARLIMS Technologies
SterilMed
Surgipath
SWOG (formerly the Southwest Oncology Group)
Synthes
Sysmex Corporation
Sysmex Group
Teva Pharmaceutical Industries
Thermo Fisher Scientific
Thermo Scientific
Tianjin Medical University Cancer Institute and Hospital (China)
TOA Corporation
TOA Medical Electronics
Tocagen
Tosoh
Transasia Bio Medicals
Van Andel Research Institute
Ventana
Veridex
Vermillion
ViiV Healthcare
Virco

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44-(0)20-7336-6100